Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

VSMPO-AVISMA to build a long product rolling complex for ₽21 billion

7/12/23 VSMO

Ozon will invest ₽8 billion to create a logistics hub in Saratov

7/12/23 OZON

HSCI will allocate 40-60% of profits to dividends

7/12/23 ABIO

Novatek increased LNG sales on international markets by 53%

7/12/23 NVTK

Whoosh launched electric bicycle rental in Moscow

7/12/23 WUSH

Ashinsky Metzavod will leave the stock exchange

7/12/23 AMEZ

Svetofor will train high school students in St. Petersburg

7/12/23 SVET

Lukoil and KazMunaiGas to close the Zhenis project

7/11/23 LKOH

SPB Exchange has set up a chain of safe custody for assets from Hong Kong

7/11/23 SPBE

Poland has started the process of selling the property of Novatek's Polish subsidiary

7/11/23 NVTK